Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma
Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Red light therapy for repairing spinal cord injury passes milestone
Patients with spinal cord injury (SCI) could benefit from a future treatment to repair nerve connections using red and near-infrared light. The method, invented by scientists at the University of…
Insect research is revolutionized by technology
New technologies can revolutionise insect research and environmental monitoring. By using DNA, images, sounds and flight patterns analysed by AI, it’s possible to gain new insights into the world of…
X-ray satellite XMM-newton sees ‘space clover’ in a new light
Astronomers have discovered enormous circular radio features of unknown origin around some galaxies. Now, new observations of one dubbed the Cloverleaf suggest it was created by clashing groups of galaxies….
